News

Subcutaneous, as opposed to intravenous, delivery of trastuzumab is equally effective for the treatment of women with HER2-positive breast cancer, and takes just 5 minutes to administer.
SC formulation takes two to five minutes to administer, rather than up to 90 minutes with the standard intravenous (IV) formulation MISSISSAUGA, ON, Sept. 13, 2018 /CNW/ - Hoffmann-La Roche ...
"Our findings show that subcutaneous administration was significantly faster than intravenous administration across all measured outcomes, including patient time in the treatment chair (primary ...
Pellegrino B, Tommasi C, Serra O, et al. Randomized, open-label, phase II, biomarker study of immune-mediated mechanism of action of neoadjuvant subcutaneous trastuzumab in patients with locally ...
Subcutaneous administration of trastuzumab and pertuzumab significantly shortened the time patients with stage I HER2-positive breast cancer spent getting treatment compared with IV delivery ...
Subcutaneous trastuzumab was observed to have a safety profile and efficacy similar to standard IV administration, offering a viable treatment alternative, according to study results published ...
Subcutaneous trastuzumab therapy for HER2-positive early breast cancer in the routine clinical practice: First interim analysis of the National Non-Interventional Study (NIS) HerSCin. Authors : Marcus ...
Initial administration of Phesgo’s fixed-dose combination of pertuzumab and trastuzumab—the therapeutic ingredients which are identical to IV pertuzumab and IV trastuzumab—with ...
Herceptin (Trastuzumab) Subcutaneous (SC) Formulation Approved In Canada For Treatment Of Her2-Positive Breast Cancer. By Reuters. September 13, 2018 12:16 PM UTC Updated ago Sept 13 ...
Embracing Subcutaneous Drugs in Lung Cancer and Beyond — Patients by far prefer subcutaneous to intravenous medication delivery, says Jorge Nieva, MD by Greg Laub , Director, Video, MedPage ...